Back

Identification of Conserved Immune-Related Adverse Event Risk Factors and Clinical Outcomes in a Pan-Immunotherapy Data Mart

2025-06-06 oncology Title + abstract only
View on medRxiv
Show abstract

BackgroundCancer immunotherapy often triggers immune-related adverse events (irAEs). Analysis of irAEs in large checkpoint inhibitor (CPI) trials has enhanced their management and demonstrated their prognostic value for treatment outcome. However, data on irAEs in non-standard cancer immunotherapies (CITs) are limited, and systematic exploration is lacking. Identifying predictive biomarkers for irAEs in these therapies is still emerging and essential for improving patient care. MethodsWe establ...

Predicted journal destinations